Nathalie Clement, Ph.D.
Dr. Clement has more than 20 years of experience in the field of Gene Therapy, with a strong expertise in viral vectors, specifically adeno-associated vectors. During her thesis work at the University Libre of Brussels, Belgium, she developed new recombinant viruses derived from the parvovirus Minute Virus of Mice (MVM) for cancer-selective gene therapy treatments. She then joined Dr. Michael Linden’s laboratory at Mount Sinai School of Medicine, New York, where she developed novel recombinant AAV vectors and directed the AAV Vector Core. She joined the Powell Gene Therapy Center in 2008 as the Associate Director to supervise AAV production and testing at research, preclinical and clinical scales. She currently leads the Process and Development Group and the Quality Control group responsible for the production and release of all AAV pre-clinical and clinical lots. Her research is largely focused on optimizing processes supporting large-scale production of high quality rAAV stocks and their implementation into the GMP settings.